Navigation Links
Anesiva to Unveil Zingo(TM) Commercialization Plans
Date:10/4/2007

SOUTH SAN FRANCISCO, Oct 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will host a briefing for the investment community to review the company's launch and commercialization plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. The briefing will take place on Friday October 12, 2007 from noon to 1:30 p.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit http://www.anesiva.com.

Anesiva's management and will review the company's manufacturing and commercialization plans as well as the timeline for the Zingo launch. The meeting will also feature William T. Zempsky, M.D., a pediatric pain specialist and associate professor of Pediatrics and Emergency Medicine at the University of Connecticut School of Medicine, who will discuss clinical experience with Zingo and the role it can play in pediatric medicine.

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. Anesiva also recently completed enrollment of a Phase 3 trial evaluating Zingo in adults with the goal of expanding the label beyond the pediatric population.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
2. Canine Painkiller unveiled by Novartis
3. Skin cancers secrets unveiled
4. Pfizer unveils anti-smoking drug
5. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
6. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
7. Study Unveils New Insight To The Madness Of King George III
8. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
9. Rae unveils Health-care Strategy
10. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
11. New Health Insurance Scheme for Diabetics Unveiled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than ... the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” ... career as an educator interacting with countless women who had little knowledge of the ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: a ... world hunger, and shares the simple and achievable answer. “The Land of More and ... the Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Next week ... will be repealed by Congressional political games that circumvent health needs of over 30 ... Rally” capture the human anxieties and needs government public servants were suppose to prioritize. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 This report on ... and future scenario of the global market. Large number ... consumption. Severe chronic constipation is a major side effect ... laxatives. Hence, novel targeted therapy has been prescribed to ... launch of targeted medicines, and growing awareness about the ...
(Date:1/19/2017)... NEW YORK , January 19, 2017 ... global market for cryotherapy is set to witness a CAGR of ... North America will continue to be the leading ... ... Suppliers are emphasizing on ensuring affordable and adequate supply ...
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
Breaking Medicine Technology: